00:23:20 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaMERK Equities
SektorInformationsteknik
IndustriProgramvara
PatientSky Group är ett norskt bolag verksamma inom teknikbranschen. Bolaget är specialiserade inom utveckling av mjukvarulösningar. Programvaran är egenutvecklad och används huvudsakligen inom vård och omsorg för uppföljning och analys. Utöver huvudverksamheten erbjuds diverse mervärdestjänster. Störst verksamhet återfinns inom den nordiska marknaden.

Kalender

2022-11-11 Kvartalsrapport 2022-Q3
2022-08-15 Kvartalsrapport 2022-Q2
2022-05-20 Kvartalsrapport 2022-Q1
2022-02-22 Bokslutskommuniké 2021
2021-10-13 Extra Bolagsstämma 2021
2021-09-01 Kvartalsrapport 2021-Q2
2021-06-11 Ordinarie utdelning PSKY 0.00 NOK
2021-06-10 Årsstämma 2021
2021-05-14 Bokslutskommuniké 2020
2021-09-01 07:35:48
PatientSky has in recent days made a significant and important change. The key
motivation has been to ensure that we keep true to our vision of changing lives
and our mission to empower partners, patients and professionals across borders
to provide the future of new, better, faster and cheaper patient care.

The company remains highly motivated and extremely pleased to now have brought
Kristian Ikast onboard as new CEO to drive the next phase of the company's
journey: moving from a start-up to a scale-up.

The critical facet of this phase of the journey is to refocus back on being the
platform company that we set out to be from day one. Everything we do from today
and onwards will be to support and cultivate this ambition.


Q2 2021 Financial Results:

The Q2 financial performance came in line with expectations, and we are firmly
on course to reach our full-year restated guidance for 2021.

Revenue for Q2 2021 came in at NOK 51.4m up 51% YoY, with an MRR of NOK 15.5m as
of June 2021, up 44% YoY. The gross profit for Q2 was 82%, the EBITDA margin 23%
and the adj. EBITDA margin 30%.

The recurring revenue, which makes up ~90% of revenue, grew 4% QoQ. We expect
full year organic recurring revenue growth to reach 20% for 2021. Projects
declined in Q2 to 4.1m from 6.4m in Q1, explaining why the overall topline was
fairly flat QoQ. For the second half of 2021 we expect still lower projects and
consulting revenues, as we prioritize growing the higher quality recurring
revenue part of our SaaS business.

Please join our webcast at 11:00 (CEST) today (Sept. 1st):

https://www.patientsky.com/investor-relations/overview